Active Biotech Q2 operating loss narrows to SEK 10.2 million; net loss improves to SEK 10.1 million

• Active Biotech posted an operating loss of SEK 10.2 million in Q2, narrowing from SEK 11.3 million a year earlier.
• Net loss was SEK 10.1 million, improving from SEK 11.2 million; loss per share narrowed to SEK 0.38 from SEK 0.91.
• Cash and cash equivalents totaled SEK 43.9 million at June 30, up from SEK 16.8 million a year earlier.
• H1 R&D costs fell 20% to SEK 12.6 million, on lower tasquinimod costs and reduced laquinimod spending after the LION study ended.
• Management sees first protocol-defined interim analyses for tasquinimod myelofibrosis studies in Q1 2027; liquidity expected into Q4 2027.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Active Biotech AB published the original content used to generate this news brief on August 19, 2026, and is solely responsible for the information contained therein.